Establishment Labs Holdings slipped 2.2% to US$77.33 after its Q2 report, a muted move for a stock that has already been soft over the past month. The headline is simple: revenue reached US$67.5m and the company turned adjusted EBITDA positive at US$3.7m while pushing gross margin to 70.6%.

The near term story is still about losses and a premium valuation, with the stock trading on a trailing P/S of 9.3x versus much lower industry averages. The longer term question is whether the minimally invasive platform and raised 2026 revenue guidance can eventually justify that premium.

Love Establishment Labs Holdings' high gross margin and move to positive adjusted EBITDA but concerned about paying up for a stock on a rich sales multiple while it still reports losses? Take a look at our carefully filtered list of stocks that pair stronger balance sheets with healthier cash generation in the list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$67.5m vs. US$51.3m (revenue increased 31.7%)
• Net Loss, Q2 2026 vs. Q2 2025: US$11.7m loss vs. US$16.6m loss (net loss narrowed 29.2%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.39 loss per share vs. US$0.57 loss per share (loss per share improved 32.0%)
• Gross Margin, Q2 2026 vs. Q2 2025: 70.6% vs. 68.8% (gross margin expanded 1.8 percentage points)

Prefer clean visuals instead of parsing another wall of earnings figures and ratios? See Establishment Labs Holdings' revenue and profitability trend presented in a clear, interactive format in the full company report for Establishment Labs Holdings.

Evaluating Whether ESTA’s Growth Engine Is Delivering

The bullish story around Establishment Labs is that differentiated implants and minimally invasive procedures can expand the breast aesthetics market, support premium pricing, and pull the company toward sustainable profitability. Q2 gives concrete milestones against that story. U.S. revenue reached US$24.7m and now accounts for 36.6% of sales, which supports the claim of strong surgeon adoption and patient pull in that market. Minimally invasive procedures, including Preservé, produced US$12.1m in the quarter and are tracking toward about 15% of full year revenue. That backs the idea that these offerings are becoming a meaningful second leg of the business rather than a side product.

On the profitability side, gross margin of 70.6% and a shift to US$3.7m of adjusted EBITDA reflect the kind of operating progress bulls have been looking for. Positive quarterly cash flow and higher cash on hand further support the transition narrative.

Compare Establishment Labs Holdings' margin gains and cash flow progress with what the street is pricing in right now. See the consensus price target analysis for Establishment Labs Holdings

Bear Case On Profitability And Concentration Still Intact

The harshest critics of Establishment Labs Holdings argue that heavy investment, concentration in breast aesthetics and regulatory risk could keep true profitability out of reach. Q2 chips away at that but does not close the file. Adjusted EBITDA of US$3.7m and positive cash flow show operating leverage is starting to work, which directly challenges fears that costs would always outrun gross profit. Cash on hand also moved up to US$71.2m, which takes some immediate financial pressure off.

However, the company still reports a net loss of US$11.7m and remains reliant on a single core category while reconstruction revenue is pushed into 2027 or later. That supports the concentration and timing parts of the bearish narrative. The small share price decline since the print suggests investors are not treating this quarter as a clean break from those concerns.

With a premium P/S, ongoing losses and a still developing cash position, it is worth verifying whether Establishment Labs Holdings has the balance sheet strength to support its plans. Check the full financial health analysis of Establishment Labs Holdings stock.

Stay Ahead Of Your Next Move

If Establishment Labs Holdings’ premium P/S and shift to positive adjusted EBITDA have caught your attention, register for free with Simply Wall St and add it to a Watchlist to watch how the share price tracks against fair value and spot a potential entry that fits your plan. After you own the stock, use the Portfolio Command Center to cut through noise and focus on key developments that really matter to your holdings. For a broader context around your thesis, turn to the Community to see how other investors are thinking about opportunities and risks. This way you can surface hidden catalysts or early warning signs sooner and stay a step ahead of the market.

Seeking Alternatives Before Momentum Flies

Fresh ideas move first and often move fast. Spot potential breakouts and fading stories while they are still under the radar for now. The clock is ticking, get in early.

• Track rising income stories and steady payers by reviewing 8 dividend fortresses, curated for investors who want cash returns working while share price momentum builds or drops around them.
• Hunt for emerging leaders in computing by scanning 26 quantum computing stocks, a focused set of businesses where progress in next generation hardware and software could shift sentiment before the crowd catches on.
• Zero in on real world AI adoption with 36 robotics and automation stocks, highlighting companies using automation and intelligent machines to drive operational change while the story is still developing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.